[go: up one dir, main page]

WO2012077932A3 - Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant - Google Patents

Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant Download PDF

Info

Publication number
WO2012077932A3
WO2012077932A3 PCT/KR2011/009224 KR2011009224W WO2012077932A3 WO 2012077932 A3 WO2012077932 A3 WO 2012077932A3 KR 2011009224 W KR2011009224 W KR 2011009224W WO 2012077932 A3 WO2012077932 A3 WO 2012077932A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridine derivative
same
pharmaceutically acceptable
pharmaceutical composition
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/009224
Other languages
English (en)
Korean (ko)
Other versions
WO2012077932A2 (fr
Inventor
김명화
구일회
천광우
류동규
최정훈
김영하
조보영
박지선
이한창
김강전
김승현
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jeil Pharmaceutical Co Ltd
Original Assignee
Jeil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeil Pharmaceutical Co Ltd filed Critical Jeil Pharmaceutical Co Ltd
Publication of WO2012077932A2 publication Critical patent/WO2012077932A2/fr
Publication of WO2012077932A3 publication Critical patent/WO2012077932A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne un nouveau dérivé de pyrazole pyridine ou des sels de qualité pharmaceutique de celui-ci, leur procédé de production, et une composition pharmaceutique les contenant. Le nouveau dérivé de pyrazole pyridine selon la présente invention inhibe la GSK-3β, et peut être efficacement utilisé pour prévenir ou traiter les troubles liés à la démence, à la maladie d'Alzheimer, à la maladie de Parkinson, au parkinsonisme variante démence frontotemporale, au complexe Parkinson-démence de Guam, à la démence due au VIH, ou aux pathologies liées à des enchevêtrements neurofibrillaires.
PCT/KR2011/009224 2010-12-07 2011-11-30 Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant Ceased WO2012077932A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0124391 2010-12-07
KR1020100124391A KR20120063283A (ko) 2010-12-07 2010-12-07 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2012077932A2 WO2012077932A2 (fr) 2012-06-14
WO2012077932A3 true WO2012077932A3 (fr) 2012-09-07

Family

ID=46207575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009224 Ceased WO2012077932A2 (fr) 2010-12-07 2011-11-30 Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant

Country Status (2)

Country Link
KR (1) KR20120063283A (fr)
WO (1) WO2012077932A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487159A1 (fr) 2011-02-11 2012-08-15 MSD Oss B.V. Inhibiteurs du RORgammaT
WO2014026327A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'acide benzoïque à substitution 4-hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
WO2014026330A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés 3-aminocycloalkyles en tant qu'inhibiteurs de rorgammat et leurs utilisations
CN105712992B (zh) * 2012-09-29 2018-10-26 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
EA031104B1 (ru) 2014-06-03 2018-11-30 Идорсиа Фармасьютиклз Лтд Пиразольные соединения и их применение в качестве блокаторов кальциевых каналов т-типа
AU2015317022B2 (en) 2014-09-15 2020-01-16 Idorsia Pharmaceuticals Ltd Triazole compounds as T-type calcium channel blockers
WO2016130818A1 (fr) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Composés pyrazole substitués utilisés en tant qu'inhibiteurs de rorgammat et utilisations desdits composés
CA3002846A1 (fr) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Composes pyrazoles bicycliques substitues en tant qu'inhibiteurs de rorgammat et leurs utilisations
CA3002853A1 (fr) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Acides benzoiques a substitution heteroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
KR102612136B1 (ko) * 2015-11-10 2023-12-08 고쿠리쓰다이가쿠호진 규슈다이가쿠 디시아노피라진 화합물, 발광 재료, 그것을 사용한 발광 소자, 및 2,5-디시아노-3,6-디할로게노피라진의 제조 방법
KR102296653B1 (ko) 2016-12-16 2021-09-01 이도르시아 파마슈티컬스 리미티드 T-유형 칼슘 채널 차단제를 포함하는 약학 조합물
EP3577099B1 (fr) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd Un procédé nouveau pour la préparation des 1-aryl-1-trifluorométhylcyclopropanes
US20230250088A1 (en) * 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
EP4274659A1 (fr) * 2021-01-08 2023-11-15 IFM Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting
CA3223223A1 (fr) 2021-06-28 2023-01-05 Blueprint Medicines Corporation Inhibiteurs de cdk2
CN118126038B (zh) * 2024-05-08 2024-07-12 烟台大学 吡唑并吡啶类衍生物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045949A1 (fr) * 2001-11-26 2003-06-05 Smithkline Beecham P.L.C. Derives de pyrazolopyridine
WO2003068773A1 (fr) * 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
WO2004013140A1 (fr) * 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Compositions pyrazole convenant comme inhibiteurs de gsk-3
WO2009145814A2 (fr) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases
WO2010104306A2 (fr) * 2009-03-07 2010-09-16 주식회사 메디젠텍 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045949A1 (fr) * 2001-11-26 2003-06-05 Smithkline Beecham P.L.C. Derives de pyrazolopyridine
WO2003068773A1 (fr) * 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
WO2004013140A1 (fr) * 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Compositions pyrazole convenant comme inhibiteurs de gsk-3
WO2009145814A2 (fr) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases
WO2010104306A2 (fr) * 2009-03-07 2010-09-16 주식회사 메디젠텍 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme

Also Published As

Publication number Publication date
WO2012077932A2 (fr) 2012-06-14
KR20120063283A (ko) 2012-06-15

Similar Documents

Publication Publication Date Title
WO2012077932A3 (fr) Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant
HK1231471A1 (zh) 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
IN2012DN02968A (fr)
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
HRP20110524T1 (hr) Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
WO2012162254A8 (fr) Inhibiteurs de l'activité lrrk2 kinase
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2009010407A (es) Derivados fluorados de deferiprona.
WO2014045162A8 (fr) Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
HK1202448A1 (en) Topical formulation for administering a compound
MX368157B (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
WO2014015056A3 (fr) Médicaments anti-mucus et leurs utilisations
IN2014DN09347A (fr)
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
WO2014141035A3 (fr) Dérivés hétérocyclyles fusionnés en tant qu'inhibiteurs nampt
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
WO2014167577A3 (fr) Synthèse du dabigatran
PH12013501509A1 (en) Treatment of cognitive dysfunction in schizophrenia
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
WO2014160143A3 (fr) Composés d'isatine, compositions et procédés pour le traitement de maladies et de troubles dégénératifs
WO2011094434A3 (fr) Dérivés de 7-azoniabicyclo[2.2.1]heptane, procédés de production, et utilisation pharmaceutiques de ceux-ci
WO2012150829A3 (fr) Dérivé de triazolopyridine noble ou sels pharmaceutiquement acceptables de celui-ci, procédé de production de celui-ci, et composition pharmaceutique comprenant celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847604

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11847604

Country of ref document: EP

Kind code of ref document: A2